Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Hypersensitivities01:30

Hypersensitivities

Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

10 Ways to improve your recognition of inborn errors of immunity.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2025
Same author

Poor diagnostic performance of flow volume loops for detection of inducible laryngeal obstruction/vocal cord dysfunction.

The journal of allergy and clinical immunology. In practice·2025
Same author

Non-β-Lactam Antibiotic Use, β-Lactam Allergy, and Surgical Site Infections.

JAMA surgery·2025
Same author

Factors associated with and kinetics of anti-IFN-α autoantibodies in <i>RAG1/2</i> deficiency.

The journal of allergy and clinical immunology. Global·2025
Same author

Allergy to "Hypoallergenic" Gel Nail Polish.

The journal of allergy and clinical immunology. In practice·2025
Same author

The Impact of Climate, Aeroallergens, Pollution, and Altitude on Exercise-Induced Bronchoconstriction.

Immunology and allergy clinics of North America·2024

Related Experiment Video

Updated: May 16, 2026

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

Omalizumab and hypersensitivity reactions.

Tara Shankar1, Andrej A Petrov

  • 1Department of Medicine, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA.

Current Opinion in Allergy and Clinical Immunology
|December 18, 2012
PubMed
Summary

Omalizumab effectively prevents hypersensitivity reactions and may treat anaphylaxis. This anti-IgE antibody shows promise for allergic conditions and has a low risk of causing anaphylaxis itself.

More Related Videos

Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis
08:25

Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis

Published on: September 26, 2022

Related Experiment Videos

Last Updated: May 16, 2026

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis
08:25

Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis

Published on: September 26, 2022

Area of Science:

  • Immunology
  • Allergology
  • Pharmacology

Background:

  • Omalizumab is an anti-IgE monoclonal antibody approved for moderate-to-severe allergic asthma.
  • Its off-label applications in preventing IgE-mediated hypersensitivity reactions are under investigation.
  • Anaphylaxis associated with omalizumab treatment has also been reviewed.

Purpose of the Study:

  • To review published studies and case reports on the off-label use of omalizumab for preventing IgE-mediated hypersensitivity reactions.
  • To examine anaphylaxis occurring during omalizumab treatment.

Main Methods:

  • Literature review of published studies and case reports.
  • Analysis of data on omalizumab's efficacy and safety in hypersensitivity reactions.
  • Review of anaphylaxis cases linked to omalizumab.

Main Results:

  • Omalizumab demonstrated efficacy in preventing various hypersensitivity and anaphylactic reactions.
  • A randomized study showed partial improvement in peanut tolerance in allergic patients.
  • Combination therapy with omalizumab and immunotherapy reduced systemic reactions and improved outcomes.
  • The risk of anaphylaxis with omalizumab is low, with successful desensitization reported.

Conclusions:

  • Omalizumab is effective and well-tolerated for reducing hypersensitivity reactions in allergic rhinitis and mild-to-moderate asthma patients undergoing immunotherapy.
  • Omalizumab shows potential as a therapy for anaphylaxis, warranting further randomized studies.
  • Further research is needed to understand the mechanism of omalizumab-induced anaphylaxis.